Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -68.50% is 123% below its 5-year average of -30.76%, near the low end of its 5-year range (-68.50%–15.71%).
130.02% below its 12-month average of -29.78%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.79%.
RETURN ON ASSETS (ROA)
-68.50%
RETURN ON ASSETS (ROA) AVG TTM
-29.78%
RETURN ON ASSETS (ROA) AVG 3Y
-39.51%
RETURN ON ASSETS (ROA) AVG 5Y
-30.76%
RETURN ON ASSETS (ROA) AVG 10Y
-63.27%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-130.02%
CURRENT VS 3Y AVG
-73.40%
CURRENT VS 5Y AVG
-122.68%
CURRENT VS 10Y AVG
-8.26%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-154.65%
vs the sector median at left
Coherus Oncology, Inc.
Market Cap
$174.59M
Return on Assets (ROA)
-68.50%
TTM Avg
-29.78%
3Y Avg
-39.51%
5Y Avg
-30.76%
Market Cap
$178.29M
Return on Assets (ROA)
-38.62%
TTM Avg
-32.73%
3Y Avg
-28.05%
5Y Avg
-37.08%
Market Cap
$178.17M
Return on Assets (ROA)
-41.88%
TTM Avg
-12.18%
3Y Avg
-27.40%
5Y Avg
-32.78%
Market Cap
$175.94M
Return on Assets (ROA)
-534.43%
TTM Avg
-94.69%
3Y Avg
-82.47%
5Y Avg
-71.30%
Market Cap
$180.47M
Return on Assets (ROA)
-17.38%
TTM Avg
-167.34%
3Y Avg
-136.62%
5Y Avg
-286.91%
Market Cap
$160.13M
Return on Assets (ROA)
-50.30%
TTM Avg
-131.74%
3Y Avg
-92.52%
5Y Avg
-67.08%
Market Cap
$184.12M
Return on Assets (ROA)
-6.21%
TTM Avg
-15.18%
3Y Avg
-15.88%
5Y Avg
-16.43%
Market Cap
$160.82M
Return on Assets (ROA)
-8.61%
TTM Avg
-9.87%
3Y Avg
-17.96%
5Y Avg
-12.40%
Market Cap
$154.72M
Return on Assets (ROA)
-35.50%
TTM Avg
-18.07%
3Y Avg
-62.20%
5Y Avg
-134.72%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | $174.59M | -68.50% | -29.78% | -39.51% | -30.76% |
| Compass Therapeutics, Inc. (CMPX)vs › | $178.29M | -38.62% | -32.73% | -28.05% | -37.08% |
| Precision BioSciences, Inc. (DTIL)vs › | $178.17M | -41.88% | -12.18% | -27.40% | -32.78% |
| Cue Biopharma, Inc. (CUE)vs › | $175.94M | -534.43% | -94.69% | -82.47% | -71.30% |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | -17.38% | -167.34% | -136.62% | -286.91% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $160.13M | -50.30% | -131.74% | -92.52% | -67.08% |
| Journey Medical Corporation (DERM)vs › | $184.12M | -6.21% | -15.18% | -15.88% | -16.43% |
| Inogen, Inc. (INGN)vs › | $160.82M | -8.61% | -9.87% | -17.96% | -12.40% |
| LifeMD, Inc. (LFMDP)vs › | $154.72M | -35.50% | -18.07% | -62.20% | -134.72% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $154.57M | -90.55% | -70.80% | -45.07% | -40.08% |
ROA
-68.5%
ROE
-215.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -65.92% |
| 2024-12-31 | 6.36% |
| 2023-12-31 | -37.78% |
| 2022-12-31 | -60.68% |
| 2021-12-31 | -42.26% |
| 2020-12-31 | 15.71% |
| 2019-12-31 | 21.97% |
| 2018-12-31 | -210.46% |
| 2017-12-31 | -146.47% |
| 2016-12-31 | -71.34% |
| 2015-12-31 | -105.12% |
| 2014-12-31 | -46.54% |
| 2013-12-31 | -113.04% |
| 2012-12-31 | -124.44% |
